Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 16, 2007

Pfizer to Procure Coley for $164M

  • Pfizer entered into an agreement to acquire Coley Pharmaceuticals, a pioneer of a new class of drug candidates called TLR Therapeutics, for a cash tender offer for all of Coley’s outstanding stock at $8 per share, totaling $164 million.

    Coley has an established pipeline of TLR Therapeutic, which work by stimulating or blocking immune system receptors called Toll-like receptors (TLRs), product candidates currently advancing through clinical development for targeting TLRs 7, 8, and 9. This class of immunomodulatory drug candidates are designed to fight cancers, allergy and asthma disorders, and autoimmune diseases.

    “This acquisition is an important component of Pfizer’s vaccine strategy and reflects our commitment to research new and more effective vaccines to prevent infectious diseases and to treat cancers and other debilitating conditions. Coley’s innovative product candidate portfolio and technology have the potential to significantly enhance future vaccine and immunotherapeutic approaches to a broad range of diseases including Alzheimer’s, asthma, infectious disease, and oncology where we already have strong collaborative research in place,” says Jeffrey B. Kindler, chairman and CEO at Pfizer.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »